Attention-deficit/hyperactivity disorder: Use of cognitive evoked potential (P300) to predict treatment response

Sangal, R. Bart; Sangal, JoAnne M.

doi:10.1016/j.clinph.2006.06.004

Cited by 27 publications

(29 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have published several papers demonstrating that P300 topography can be used for this purpose [19,[25][26][27][28]. Although we found P300 variables that predicted robust treatment response, we found no clinical predictors of robust treatment response with any of these medicines.…”

Section: Evoked Potentials and Adhdcontrasting

confidence: 68%

See 1 more Smart Citation

Attention-deficit/hyperactivity disorder: using P300 topography to choose optimal treatment

Sangal¹,

Sangal

2006

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder is the most prevalent behavioral disorder in children, and persists into adulthood. Stimulants (methylphenidate and amphetamines) with dopaminergic mechanisms are the most commonly used pharmacological treatment. Nonselective (desipramine and imipramine) and selective (atomoxetine) norepinephrine reuptake inhibitors can also be effective. What constitutes a sufficient response to treatment? Too often a partial response, leaving the patient symptomatic, is accepted. If response is defined more strictly, allowing for a return to normal, then the usually quoted 70% response rates to any given attention-deficit/hyperactivity disorder medicine drop to approximately 40%. With different medicines and not enough patients responding robustly to any given medicine, we can use medicines sequentially to find the medicine that produces a robust response. Alternatively, P300 topography can be used to select optimal treatment.

show abstract

Section: Evoked Potentials and Adhdcontrasting

confidence: 68%

“…We then performed P300 topography in 59 ADHD subjects aged 6-14 years, participating in a double-blind crossover study of treatment effects of atomoxetine and methylphenidate in ADHD [28]. Subjects met DSM-IV criteria for ADHD, with no other significant psychiatric disorder or primary sleep disorder.…”

Section: P300 Topography and Methylphenidatementioning

confidence: 99%

Attention-deficit/hyperactivity disorder: using P300 topography to choose optimal treatment

Sangal¹,

Sangal

2006

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…However, they did not examine MMN in these patients. Another study using electrocardiogram analysis indicated that P300 amplitude predicts the differential response locations associated with these two drugs in ADHD patients (Sangal and Sangal, 2006). These studies do not agree with regards to the affected electrode.…”

Section: Discussionmentioning

confidence: 97%

Event-related potentials reflect the efficacy of pharmaceutical treatments in children and adolescents with attention deficit/hyperactivity disorder

Yamamuro

Ota

Iida

et al. 2016

Psychiatry Research

View full text Add to dashboard Cite

“…ajp.psychiatryonline.org methylphenidate using the ADHD Rating Scale that have been conducted and reported by other investigators (17,18).…”

Section: Methodsmentioning

confidence: 98%

Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response

Newcorn

Kratochvil²,

Allen³

et al. 2008

AJP

294

265

View full text Add to dashboard Cite

show abstract

Attention-deficit/hyperactivity disorder: Use of cognitive evoked potential (P300) to predict treatment response

Cited by 27 publications

References 11 publications

Attention-deficit/hyperactivity disorder: using P300 topography to choose optimal treatment

Attention-deficit/hyperactivity disorder: using P300 topography to choose optimal treatment

Event-related potentials reflect the efficacy of pharmaceutical treatments in children and adolescents with attention deficit/hyperactivity disorder

Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response

Contact Info

Product

Resources

About